



**MediPharm Labs**

**(TSX: LABS)**

**MEDIPHARM LABS CORP.**

**MANAGEMENT'S DISCUSSION AND ANALYSIS  
FOR THE THREE AND NINE MONTHS ENDED SEPTEMBER 30, 2023**

**NOVEMBER 13, 2023**

This Management's Discussion and Analysis ("MD&A") of the financial condition and performance of MediPharm Labs Corp. (the "Company", "MediPharm", "we", "us" or "our") for the three and nine months ended September 30, 2023, was prepared by management of the Company as of November 13, 2023. Throughout this MD&A, unless the context indicates or requires otherwise, the terms the "Company", "MediPharm", "we", "us" and "our" refer to MediPharm Labs Corp. together with its subsidiaries. This MD&A should be read in conjunction with our unaudited condensed interim consolidated financial statements for the three and nine months ended September 30, 2023 (the "Financial Statements"), including the accompanying notes thereto.

This MD&A has been prepared with reference to the MD&A disclosure requirements established under National Instrument 51-102 *Continuous Disclosure Obligations* of the Canadian Securities Administrators and Staff Notice 51-352 (Revised) *Issuers with US Marijuana Related Activities* (the "Staff Notice").

Additional information regarding the Company, including in the Financial Statements and our most recent annual information form dated March 30, 2023 for the year ended December 31, 2022 (the "Annual Information Form"), is available on the Company's website at [www.medipharmlabs.com](http://www.medipharmlabs.com) and under the Company's SEDAR profile at [www.sedar.com](http://www.sedar.com).

This MD&A contains commentary from the Company's management regarding the Company's strategy, operating results, financial position, and outlook. Our management is responsible for the accuracy, integrity and objectivity of the disclosure contained in this MD&A and develops, maintains, and supports the necessary systems and controls to provide reasonable assurance as to the accuracy of the comments contained herein.

Our board of directors (the "Board of Directors") and audit committee (the "Audit Committee") provide an oversight role with respect to all Company public financial disclosures. The Board of Directors approved the Financial Statements and MD&A after the completion of its review and recommendation for approval from the Audit Committee, which meets periodically to review all financial reports, prior to filing.

The Financial Statements and accompanying notes were prepared in accordance with International Financial Reporting Standards ("IFRS") as issued by the International Accounting Standards Board ("IASB") and include the accounts of the Company and its subsidiaries and the Company's interests in affiliated companies. All intercompany balances and transactions have been eliminated on consolidation. All dollar amounts are expressed in thousands of Canadian dollars (C\$'000s), other than share and per share amounts, unless otherwise noted.

In addition to historical information, the discussion in this MD&A contains forward-looking statements. The discussion is qualified in its entirety by the "Cautionary Note Regarding Forward-Looking Statements" that follows.

<b>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</b>
---

This MD&A contains forward-looking information and forward-looking statements within the meaning of Canadian securities legislation (“**forward-looking statements**”) including but not limited to:

- assumptions and expectations related to the Arrangement (as defined herein), including the revenue and cost synergies that may be realizable as a result thereof;
- assumptions and expectations described in the Company’s critical accounting policies and estimates;
- the Company’s expectations regarding legislation, regulations and licensing related to the import, export, processing, and sale of cannabis products by the Company, along with the market demand and pricing for such products;
- the ability to enter and participate in international market opportunities;
- assumptions and expectations related to the Company’s expansion into the United States pharmaceutical market;
- product diversification and future corporate development;
- anticipated results of research and development;
- production capacity expectations including discussions of plans or potential for expansion of capacity at existing or new facilities;
- expectations with respect to future expenditures and capital activities;
- statements about expected use of proceeds from fund raising activities; and
- the Company’s expectations regarding the adoption and impact of certain accounting pronouncements.

These forward-looking statements are made as of the date of this MD&A and the Company does not intend, and does not assume, any obligation to update these forward-looking statements, except as required under applicable securities legislation. Forward-looking statements relate to future events or future performance and reflect management’s expectations or beliefs regarding future events. In certain cases, forward-looking statements can be identified by the use of words such as “considers”, “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”, or the negative of these terms or comparable terminology. In this document, certain forward-looking statements are identified by words including “may”, “future”, “expected”, “will”, “intends”, and “estimates”. By their very nature forward-looking statements involve known and unknown risks, uncertainties, and other factors, which may cause the actual results, performance, or achievements of the Company to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. The Company provides no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements.

Risks related to forward-looking statements include, among other things, those outlined in “Risk Factors” and any other factors and uncertainties disclosed from time-to-time in the Company’s filings with the Canadian Securities Administrators. Although the Company has attempted to identify important factors that could cause actions, events or results to differ materially from those described in the forward-looking statements, there may be other factors that cause actions, events, or results to differ from those anticipated, estimated or intended. Given these uncertainties, readers are cautioned not to place undue reliance on such forward-looking statements.

## USE OF NON-IFRS FINANCIAL MEASURES

This MD&A contains references to “EBITDA”, “Adjusted EBITDA”, which are non-IFRS financial measures. Management believes that these supplementary non-IFRS financial measures provide useful additional information related to the operating results of the Company. These non-IFRS financial measures are not recognized under IFRS and, accordingly, users are cautioned that these measures should not be construed as alternatives to net income (loss) and gross profit determined in accordance with IFRS as measures of profitability or as alternatives to the Company’s IFRS-based Financial Statements. The non-IFRS measures presented may not be comparable to similar measures presented by other issuers.

EBITDA and Adjusted EBITDA do not have any standardized meanings and the Company’s method of calculating such non-IFRS measures may not be comparable to calculations used by other companies bearing the same description.

See “Reconciliation of Non-IFRS Measures”.

### EBITDA

EBITDA refers to earnings before interest, taxes, depreciation, and amortization and is used as an indicator of the Company’s overall profitability.

### Adjusted EBITDA

Adjusted EBITDA is a measure of the Company’s overall financial performance and is used as an alternative to earnings or income in some circumstances. Adjusted EBITDA is essentially net income (loss) with interest, taxes, depreciation and amortization, non-cash adjustments and other unusual or non-recurring items added back. Adjusted EBITDA has limitations as an analytical tool as it does not include depreciation and amortization expense, restructuring related severance expense, government grants including rent and wage subsidies, transaction fees, write down of inventory, impairment of fixed assets and intangibles, impairment loss on assets held for sale, impairment of receivables, share-based compensation, fair value adjustments to biological assets and inventory, and severance for restructuring. Because of these limitations, Adjusted EBITDA should not be considered as the sole measure of the Company’s performance and should not be considered in isolation from, or as a substitute for, analysis of the Company’s results as reported under IFRS. Adjusted EBITDA, as used within this MD&A and the Company’s disclosure, may not be directly comparable to Adjusted EBITDA used by other reporting issuers.

## COMPANY OVERVIEW

### Background

MediPharm is a pharmaceutical company specializing in precision-based cannabinoids. Through its wholesale and other platforms, MediPharm formulates, develops, processes, packages and distributes cannabis active ingredients and advanced cannabinoid-based products to domestic and international markets.

On January 23, 2017, the Company was incorporated under the *Business Corporations Act* (Ontario) (the "OBCA") as "POCML 4 Inc.", under the policies of the TSX Venture Exchange (the "TSXV"). On October 1, 2018, MediPharm Labs Inc. ("MediPharm Labs") amalgamated with 2645354 Ontario Inc., a wholly owned subsidiary of the Company, which resulted in the reverse take-over of the Company by MediPharm Labs, following which the resulting Company continued as "MediPharm Labs Corp".

On October 4, 2018, the common shares in the capital of the Company (the "Common Shares") commenced trading on a post-consolidation basis on the TSXV under the symbol "LABS", and on July 29, 2019, the Company graduated from the TSXV to the Toronto Stock Exchange (the "TSX"). The Company's Common Shares also trade on the OTCQB in the US under the ticker symbol "MEDIF" and on the Frankfurt Stock Exchange under the ticker symbol "MLZ".

The Company's operations are currently conducted through MediPharm Labs, a wholly owned subsidiary, which holds several licences, including a Drug Establishment Licence ("DEL"), and a standard processing licence and research licence under the *Cannabis Act* (Canada) (the "Cannabis Act"). MediPharm Labs' facility holds Good Manufacturing Practice ("GMP") certifications from Health Canada and the Australian Therapeutic Goods Association. These GMP certifications have been accepted in other international markets such as Brazil and the European Union.<sup>1</sup> MediPharm Labs has filed a Drug Master File ("DMF") for cannabidiol ("CBD") with the United States Food and Drug Administration ("FDA") and is the only commercial cannabis company in Canada registered as an active FDA establishment registration.

On October 6, 2022, the Company completed the sale of its formerly wholly-owned subsidiary MediPharm Labs Australia Pty Ltd., which held a manufacturing licence under the Australian Narcotics Drug Act 1967 authorizing the manufacture and supply of certain limited cannabis products, to OneLife Botanicals Pty., a local operator (the "MPLA Divestment").

On April 1, 2023, the Company acquired VIVO Cannabis Inc. ("VIVO") pursuant to an all-equity business combination transaction, completed by way of a plan of arrangement under section 192 of the *Business Corporations Act* (Canada) (the "Arrangement"). As a result of the Arrangement, the Company acquired Canna Farms Limited ("Canna Farms") and ABcann Medicinal Inc. ("ABcann"), two wholly-owned licence holders under the Cannabis Act, both of which hold licences to produce and sell dried cannabis and cannabis oils, and to cultivate and produce cannabis products for direct sale to medical patients across Canada, as well as for retail adult-use sales. Canna Farms' operations focus on indoor cannabis cultivation, packaging, solventless extraction and concentrate production, and supporting patients through its medical e-commerce platform. ABcann's operations focus on European Union Good Manufacturing Practices ("EU GMP") related cultivation and packaging for international markets. The Arrangement also expanded the Company's reach to medical patients in Australia and Germany through Beacon Medical Australia PTY Ltd. ("Beacon Medical Australia") and Beacon Medical German GmbH ("Beacon Medical Germany") and, together with Beacon Medical Australia, the "Beacon Medical Brand". The Arrangement also

---

<sup>1</sup> As a member of Pharmaceutical Inspection Co-operation Scheme.

included the wholly-owned subsidiary Harvest Medicine Inc. (“**Harvest Medicine**” or “**HMED**”), which operates medical clinics in Canada that provide medical cannabis patients with physician consultations for medical cannabis education and prescriptions.

## **Business Overview**

The Company specializes in the production of purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (“**API**”) and advanced derivative products utilizing GMP certified facilities and ISO standard-built clean rooms. The Company has invested in an expert, research driven team, state-of-the-art technology, downstream purification methodologies and purpose-built facilities with primary extraction lines and finished formulated products capabilities used to deliver pure, trusted and precisely doseable cannabis products for our customers. The Company’s formulates, processes, packages and distributes cannabis active ingredients and advanced cannabinoid-based products for domestic and international markets.

The Company also provides GMP flower sourcing, packaging, and distribution services for select international clients. In addition, the Company cultivates cannabis to sell as dried flower, pre-roll and other cannabis products for the adult use and medical markets. The Company’s mission is to become a global leader leveraging our GMP quality standards to provide specialized pharmaceutical quality derivative cannabis products and to drive future cannabis product innovation.

### **Operations and Facilities**

As of the date of this MD&A, the Company’s core business generates revenue through four primary streams:

- **Canadian Adult Use and Wellness**: This stream includes the production and sale of finished consumer packaged cannabis concentrate based products such as cannabis oil, vapes, soft chews, and capsules and other non-smokeable formats as well as dry flower and pre-rolls. These products are sold primarily to the provincial distributors.
- **Canadian Medical Cannabis**: This stream includes products that are sold to patients through the domestic medical channels such as the Canna Farms medical platform and through other licensed producers’ medical channels. It also includes the Company’s medical clinic business, Harvest Medicine. HMED consists of education-focused, patient-centric, cannabis discovery clinics, which conduct registered patient visits through its clinics and clinic partnerships, and via its telemedicine platform. HMED also offers pharmacy consultations as an additional service offering for patients as part of their medical cannabis care.
- **International Medical Cannabis**: This stream includes the production and sale of GMP tinctures and GMP dry flower to international customers outside of Canada. To date, MediPharm has sold into 10 international markets and has significant business in Australia, Germany, and Brazil. Key partners such as STADA Arzneimittel AG, Europe’s fourth largest generic drug company, continue to support this business segment in Germany. In addition, the Company’s Beacon Medical Brand has also further strengthened its presence in the Australian market. Beacon Medical Australia is currently in the top 5 brands of medical flower sales in Australia.<sup>2</sup> The Company also recently

launched Canadian produced GMP Beacon Medical Brand cannabis oil and inhalation cartridges in the Australian medical market through Beacon Medical Australia.

- **Pharmaceutical and Business to Business (“B2B”)**: This includes the production and sale of bulk cannabis concentrate based products such as concentrate, distillate and isolate to domestic and international customers. Bulk isolate includes pharmaceutical grade cannabinoids in isolate and finished good forms produced using our Canadian DEL and sold to pharmaceutical customers. For our pharma and academic partners, we also provide a range of clinical and research and development (“R&D”) capabilities including Clinical Trial Materials (CTM) for Phase 2-3 Drug Trials. Also included in this stream are contract manufacturing activities where we produce finished goods and various manufacturing steps for other licenced producers.

MediPharm Labs operates out of three manufacturing facilities in Barrie-Ontario (the “**Barrie Facility**”), Hope-British Columbia (the “**Hope Facility**”) and Napanee-Ontario (the “**Napanee Facility**”).

### **Barrie Facility**

This 70,000 sq. ft. facility has specialized and pharmaceutically validated equipment to produce high quality cannabis concentrate derivative bulk and finished good products. This includes automated filling and labeling equipment to meet the Canadian domestic adult use market needs. The Barrie Facility was built to GMP standards and received a DEL in the third quarter of 2021. The Barrie Facility is a registered foreign drug manufacturing site with the FDA and completed an onsite FDA inspection in 2022.

### **Hope Facility**

This 47,000 sq. ft. production facility was originally a VIVO facility and was the first licensed site in British Columbia for commercial cannabis production in 2013, issued to Canna Farms as licence holder. The current Canna Farms direct-to-patient medical sales e-commerce platform is managed and distributed via the Hope Facility.

### **Napanee Facility**

This 29,000 sq. ft. EU GMP facility was originally a VIVO facility, and is focused on production and supply for the international medical markets. On March 11, 2021, the Napanee Facility received EU-GMP certification from Germany's Brandenburg health authority, the Landesamt für Arbeitsschutz, Verbraucherschutz und Gesundheit.

### **Company Regulatory History**

On March 29, 2018, MediPharm Labs received its oil production licence (the “**Licence**”) pursuant to the Access to Cannabis for Medical Purposes Regulations (“**ACMPR**”) and became the first company in Canada to receive a production licence for cannabis oil production under the ACMPR without first receiving a cannabis cultivation licence. On October 17, 2018, the Cannabis Act came into force, and MediPharm Labs' Licence was transitioned from a producer's licence under the ACMPR to a standard processing licence under the Cannabis Act and Cannabis Regulations. On November 9, 2018, the Licence was amended to permit the sale and distribution of cannabis oil and derivatives to the following authorized classes of purchasers:

- a holder of a licence for processing under the Cannabis Act;
- a holder of a licence for analytical testing under the Cannabis Act;

- a holder of a licence for research under the Cannabis Act;
- a holder of a cannabis drug licence under the Cannabis Act;
- the Minister of Health;
- a person to which an exemption has been granted under section 140 of the Cannabis Act in relation to the cannabis or a class of cannabis that is sold or distributed; or
- certain individuals who are involved in testing cannabis at laboratories operated by the Government of Canada or accredited laboratories under the *Seeds Act*.

On September 7, 2019, the Licence was further amended to permit the sale of cannabis products to the following authorized classes of purchasers:

- a holder of a licence for sale of medicinal cannabis products under the Cannabis Act; and
- a person authorized to sell cannabis under a provincial Act, such as a provincially authorized retailer or distributor.

On October 21, 2019, MediPharm Labs' Licence was amended to permit the activity of production and sale of additional cannabis products included in the Cannabis Act, including cannabis extracts, cannabis edibles and cannabis topicals. On September 28, 2021, MediPharm Labs' Licence was renewed for a further term of five years and was further amended on April 25, 2022 to allow for the sale, distribution, and delivery of dried cannabis and fresh cannabis.

On October 25, 2019, MediPharm Labs received its research licence under the Cannabis Act. This licence permits MediPharm Labs to conduct controlled human administration trials for sensory testing of cannabis extracts and derivative products at its Barrie facility. Cannabis companies without this licence cannot use sensory experiments with taste, thus limiting their understanding of the taste profile of the raw material, in process material, and consumer products.

On December 21, 2020, MediPharm Labs received a GMP licence under the Natural Health Products Regulations (the "**NHP Site Licence**"). The NHP Site Licence gives MediPharm Labs the authorization to manufacture, package and label natural health products in Canada. MediPharm Labs' Barrie site follows GMP requirements outlined in Part 3 of the Natural Health Products Regulations. On December 21, 2022, the NHP Site Licence was renewed for a further one-year term.

On February 17, 2021, MediPharm Labs received a Cannabis Drug Licence ("**CD Licence**") from Health Canada. The CD Licence allows the Company to manufacture and supply drugs that contain cannabis. These products include pharmaceutical prescription drugs that have been classified as drugs with a drug identification number. The Company is positioned to supply cannabis based pharmaceutical drugs and APIs to other CD Licence holders and clinical research trials for novel drug discovery. On October 8, 2021, MediPharm Labs' CD Licence was amended to allow for the sale of drugs that contain cannabis. The amended CD Licence is valid until January 27, 2024.

On July 14, 2021, MediPharm Labs received a GMP DEL issued by Health Canada in accordance with the *Food and Drugs Act* (Canada) and associated Regulations. The DEL serves to confirm compliance to GMP standards. The DEL can be used for manufacturing, testing and sale of any non-sterile APIs and pharmaceuticals, including drug products containing cannabis. This includes drugs that have marketing authorizations as either novel or generic pharmaceutical drug products containing cannabis. MediPharm Labs is the only facility with large scale natural cannabinoid extraction capabilities that holds a GMP licence from a domestic health authority in North America.

On February 23, 2022, the Company announced that it had entered the United States pharmaceutical market with the completion of an FDA Drug Master File process for pure natural CBD APIs. The DMF allows for the registration of APIs with the FDA for commercial opportunities in pharmaceutical development, novel drugs, and generic drugs. This is a first for CBD by a Canadian company and the second natural CBD DMF at commercial scale in North America. The DMF enables MediPharm to supply approved APIs to pharmaceutical companies conducting late-stage research. The FDA has conducted an active review of the DMF filing. Full acceptance of the DMF filing by the FDA will be gained if a pharmaceutical customer completes a successful filing with the FDA for a New Drug Application (“NDA”) or Abbreviated New Drug Application (“ANDA”).

MediPharm has international pharmaceutical partners who have referenced the DMF and finished goods in either a drug product filing or FDA investigational NDA. If any of our pharmaceutical partners are successful in their United States (“U.S.”) filings, any resulting drugs containing cannabis would gain marketing authorization (through an NDA or ANDA). The drugs would be distributed across the U.S. as FDA approved pharmaceutical products, and therefore outside of any U.S. cannabis regime regulated at the state level. Seeking FDA approvals for both branded (NDAs) and generic (ANDAs) drugs and participating in Phase 2 and 3 clinical trials are long term investments and success is not guaranteed. See “Cautionary Note Regarding Forward-Looking Statements”, “Disclosure for Issuers with U.S. Marijuana-Related Activities” and “Risk Factors”.

On April 1, 2023, the Company acquired two Canadian licensed producers, one of which holds EU-GMP certification, and a subsidiary in Germany which is EU-GMP/GDP licensed and able to import cannabis products.

The statements regarding intended expansions, exports, distributions, GMP certifications and the DMF filing are forward-looking statements. The current term of the Licence ends on September 28, 2026. It is anticipated by our management that Health Canada will extend or renew the Licence at the end of or prior to the end of its term<sup>3</sup>. See “Cautionary Note Regarding Forward-Looking Statements” and “Risk Factors”.

### **Product Manufacturing and Sales**

The Company processes its inventory of dried cannabis and sells both the resulting bulk cannabis concentrates and finished formulated products. Finished formulated products are sold under the MediPharm family of brands and under customer brands through contract manufacturing arrangements. Customers that do not hold a requisite Cannabis Act or other licence rely on the Company for the complete manufacturing and distribution of the branded product. Customers that hold their own licence may directly purchase the finished or partially finished products from the Company to manage the remaining portion of the manufacturing and/or supply chain themselves and the Company would typically receive a fee per unit shipped under that arrangement. The Company has increased the breadth (product formats) and depth (stock keeping units (“SKUs”) per product format) of finished formulated product capabilities and expects to continue this expansion going forward. In addition to the core competencies listed above, the Company is

---

<sup>3</sup> This forward-looking statement is based on the following material factors and assumptions: (a) the Company assumes that it will receive a compliant rating from Health Canada and that Health Canada will renew the Licence; and (b) the Company assumes that it will continue to be in compliance with the relevant regulatory frameworks, guidelines, and requirements of Health Canada. The Company clarifies that as of the date hereof, it has received compliant ratings from Health Canada, but cannot guarantee that there will not be issues with compliance inspections that may arise in the future. Such statements are informed by, among other things, regulatory guidelines for receiving and maintaining the Licence. See “Cautionary Note Regarding Forward-Looking Statements” and “Risk Factors”.

also engaged in the sale of GMP finished good cannabis flower to international partners in branded (Beacon Medical Brand) and white label formats.

The Company commenced shipping initial cannabis oil and vape products in December 2019, and as at the date of this MD&A are currently shipping several product formats (being formulated cannabis oil bottles, topicals, gels disposable vaporizer pens, vaporizer cartridges, soft chews, dried flower, and pre-roll products) and SKUs direct to authorized distributors, provincial governments, our B2B customers and internationally.

During the Company's initial growth phase, we realized most of our revenue from product sales through long-term and spot sales of bulk crude resin and distillate. This changed in Q4 2019 as the expansion in the Canadian market for bulk concentrates seen in the ramp up to Cannabis 2.0 legalization began to slow. Over the last two years, the Company's business mix has been transformed from a narrow and primarily domestic B2B extract business to a diverse business with multiple revenue streams and an international presence. Our B2B business represented greater than 90% of sales in 2019 but represented less than 15% of sales in 2022. Following the acquisition of VIVO, B2B bulk sales now represents less than 5% of sales. The Company continues to focus on its diverse portfolio with robust Canadian adult use and wellness and international medical cannabis business streams, while the remaining B2B business is heavily focused on longer term pharmaceutical research and drug development pipelines.

### Corporate Highlights

On August 31, 2023, the Company announced that Harvest Medicine's study entitled, "*Self-Reported Effects of Illness Severity, Depression and Anxiety in Fibromyalgia Patients: A Large Retrospective Case Series*" had been published in the peer-reviewed American Journal of Endocannabinoid Medicine. The retrospective study was led by Harvest Medicine and reviewed data from 805 patients who indicated fibromyalgia as a primary reason for seeking medical cannabis and had a minimum of one follow-up assessment. The majority of patients (76.1%) reported using CBD oil, which aligns with the current practice guidelines for authorizing medical cannabis as an adjuvant therapy for managing chronic pain. The primary findings from the present study include a significant reduction in all three scores measuring depression, anxiety, and illness severity between baseline and first follow-up.

On September 5, 2023, the Company announced it had completed the sale of vacant land (the "**Kimmett Sale**"), located at 291 Kimmett's Side Road, Napanee, Ontario, for net proceeds of \$1.9 million, adding non-dilutive capital to the Company. This land was previously used by VIVO for outdoor cannabis growing but had not been utilized since 2021.

On September 20, 2023, the Company announced it had executed a supplementary agreement (the "**Supplementary Agreement**") to its asset purchase agreement from March 2022 (the "**Asset Purchase Agreement**") with 1193269 B.C. Ltd. (o/a Shelter Cannabis) ("**Shelter Cannabis**") for the Shelter Cannabis brands intellectual property ("**IP**") portfolio, ending any ongoing royalty payments after August 31, 2023. Pursuant to the Asset Purchase Agreement the Company purchased the IP of Shelter Cannabis. This IP has been focused in market on Wildlife Cannabis domestic dry flower and pre-roll products that are manufactured and distributed via the MediPharm sites. The Supplementary Agreement allows for a

significant improvement in the Shelter Brands' product line gross margin, which will provide flexibility for the Company to further invest in the brand to drive sales, as it continues on the path to profitability.

On September 27, 2023, the Company announced that GMP produced Beacon Medical cannabis oil and inhalation cartridges had been launched in the Australian medical market.

### Subsequent Events

Subsequent to the three months ended September 30, 2023, the following material developments occurred:

On October 2, 2023, the Company announced that it had entered into a settlement agreement on September 29, 2023 (the "**Settlement Agreement**") to resolve a claim in connection with a commercial agreement dispute, for a total consideration value of \$9,000. On January 24, 2020, MediPharm Labs filed a statement of claim (the "**Claim**") in the Ontario Superior Court of Justice against one of its long-term customers, HEXO Corp. ("**HEXO**"), regarding a long-term supply agreement for cannabis concentrates. The Claim related to the payment of outstanding amounts due to the Company for products shipped to and received by the customer and deposits owed to the Company for committed amounts not yet shipped. The Company was awarded a favourable summary judgment in the Ontario Court of Justice in July of 2022. The summary judgment was appealed by HEXO and a hearing at the Court of Appeal was scheduled for October 12, 2023. In connection with the Settlement Agreement, HEXO abandoned its appeal as against the Company. Upon the acquisition of HEXO by Tilray Brands, Inc. ("**Tilray**"), the Company and Tilray sought a resolution that was favorable to each party and establish a long-term supply relationship in connection with the Settlement Agreement. Under the Settlement Agreement, MediPharm will receive a total value consideration of \$9,000 including: \$3,000 immediate cash payment; \$4,500 in common shares of Tilray (the "**Tilray Shares**"); \$1,000 in Tilray cannabis products, including high-quality flower and extractable bio-mass; and \$500,000 supply agreement to provide Tilray with MediPharm products and services over four-years. The Settlement Agreement settled a current aged receivable of \$8.5 million on the Company's balance sheet.

Subsequent to September 30, 2023, the Company received the \$3,000,000 cash payment and 1,573,152 Tilray Shares which the Company disposed for net cash proceeds of \$4,250. This non-dilutive cash infusion further strengthens the Company's balance sheet. MediPharm's cash balance as of October 20, 2023 was approximately \$19.5 Million.

### Operational Highlights

In three and nine months ended September 30, 2023 ("Q3 2023"), EBITDA improved significantly driven by focus on higher margin products and markets, improvement in gross profit and ongoing cost reduction.

For Q3 2023, the Company's Adjusted EBITDA was negative \$2.4M and improved \$2.6M or 53% versus Q3 2022 and year to date Adjusted EBITDA was negative \$8.6M which improved \$8.3M or 49% versus prior year. This improvement is driven by both the improvement in gross profit and the reduction of operating expenses.<sup>4</sup>

The following is a summary of the operational highlights for the three and nine months Q3 2023, and the period subsequent to the end of the quarter.

---

<sup>4</sup> Adjusted EBITDA is a non-IFRS measure. See "Reconciliation of non-IFRS Measures" for reconciliation to IFRS measures.

**Financial Overview:** During Q3 2023, the Company's revenue of \$8.5M increased \$1.2M or 17% versus prior year largely driven by the acquisition of VIVO and partially offset by the divestiture of the Australian subsidiary at the end of Q3 2022. Revenue declined sequentially from Q2 2023 largely driven by International Medical shipment timing in the German Market. The international markets will fluctuate as the market develops and matures.

The Canadian Medical Cannabis revenue for Q3 2023 increased significantly from \$0.2M in Q3 2022 to \$3.5M in Q3 2023 driven by the integration of the VIVO medical channel. Revenue declined sequentially from \$3.8M in Q2 2023 driven by one new customer in Q2 2023 with an inventory stocking order.

International Medical revenue increased from \$2.3M in Q3 2022 to \$2.6M in Q3 2023 driven by the integration of VIVO's Australian business. Revenue declined sequentially from \$3.0M in Q2 2023 driven by shipment timing in the German Market.

The Canadian Adult Use and Wellness revenue was \$2.2M in Q3 2023 which declined versus Q3 2022 and Q2 2023 as the Company selectively increased prices, carefully managed sales, marketing expenditures and exited select products.

Pharmaceutical and B2B revenue in Q3 2023 of \$0.2M declined from \$1.4M in Q3 2022 driven by the divestiture of the MediPharm Australian subsidiary at the end of Q3 2022. Adjusting for the divestiture revenue would be consistent with prior year.

Year to date the Company's revenue increased to \$24M representing a 45% increase versus prior year same period largely driven by the acquisition of VIVO. Canadian Adult Use and Wellness year to date revenue of \$7.6M declined 7% versus prior year as the Company selectively increased prices and exited products to focus on profitability over volume. Canadian Medical Cannabis year to date revenue of \$7.9M increased \$7.2M versus prior year driven by the integration of the VIVO medical channel. International Medical Cannabis year to date revenue of \$7.4M increased 68% versus prior year driven by the integration of VIVO's Australian business. Pharmaceutical and B2B year to date revenue was \$1.0M and declined \$2.3M versus same period prior year largely driven by the divestiture of the Australian subsidiary at the end of Q3 2022.

The Company's Q3 2023 gross profit was \$2.4M/28.4% which improved significantly versus Q3 2022 of negative 16% and Q2 2023 of 8.2%. Q3 gross profit was 32% when adjusting for several discrete items such as biological asset fair value adjustments and severance for restructuring. Q2 2023 adjusted gross profit was 21%. Gross profit continues to improve, driven by product mix, production efficiencies, selective price increases and cost reductions. Management continues to focus on efficiencies to drive gross profit.

Operating expenses (general administrative expenses, marketing and selling expenses, and R&D expenses) for Q3 2023 was \$6.1M and included \$0.3M of severance expense for restructuring. Adjusting for severance and other discrete items (compensation accrual adjustments), Q3 2023 operating expenses were approximately \$5.9M. Year to date operating expenses of \$16.4M were 12% higher than prior year driven by the integration of VIVO. Adjusting for several discrete items in 2022 year to date (i.e. Severance for restructuring), operating expenses 2023 year to date would be 3% lower than 2022 year to date despite the integration of VIVO. The integration of VIVO has added approximately \$6M of operating expense year to date 2023. Retrospectively, if VIVO and Medipharm were combined for all periods, operating expense 2023 year to date has declined approximately \$10M or 34%. Management continues to focus on expense reduction opportunities.

For Q3 2023, the Company's Adjusted EBITDA was negative \$2.4M and improved \$2.6M or 53% versus Q3 2022 and year to date Adjusted EBITDA was negative \$8.6M which improved \$8.3M or 49% versus prior year. This improvement is driven by both the improvement in gross profit and the reduction of operating expenses.<sup>5</sup>

In 2022, the Company's Adjusted EBITDA averaged negative \$5-\$6 million per quarter and VIVO averaged negative \$2 million per quarter. Combined, the two companies averaged negative Adjusted EBITDA of \$7 to \$8 million per quarter in 2022. In addition, MediPharm's Q1 2023 Adjusted EBITDA was negative \$3.1 million and Q2 2023 was negative \$3.2M. This means the Company was able to incorporate VIVO and improve profitability relative to Q1 2023 largely driven by cost reduction initiatives and synergy achievement.

The Company's cash balance at the end of Q3 2023 was \$13.0M and the Company has less than \$3M of debt. Contrary to many other Cannabis companies, MediPharm is also up to date on Cannabis excise duties, sales taxes and accounts payables. During the Q3 2023 the long outstanding dispute regarding an unpaid \$8.5M receivable was resolved with a settlement for \$3M of cash, \$4.5M of Tilray shares, \$1M inventory credit and a supply agreement for \$0.5M.

Subsequent to Q3, the Company collected the \$3M cash and liquidated the Tilray shares for net proceeds of \$4.3M. This \$7.3M of cash is not included in the Company's Q3 2023 \$13.0M cash balance previously noted. In addition, the Company sold land and collected \$1.9M of cash in Q3. The Company has assets held for sale with the opportunity to generate cash of approximately \$1M.

**Cost Reduction Initiatives:** In September 2022, the Company implemented a restructuring plan that has seen a reduction in the Canadian non-manufacturing headcount by approximately 30% through the end of fiscal 2022. The Company realized some cost savings from the restructuring efforts starting in Q3 2022 and continued to realize some cost savings from the restructuring efforts in Q2 2023. The restructuring efforts are expected to reduce expenses by approximately \$3 million on an annualized basis for fiscal 2023. During Q3 2023 the Company implemented another restructuring plan to further reduce expenses by approximately \$3M on an annualized basis with the benefits starting to accrue in Q4 2023.

With the integration of VIVO starting April 1, 2023, the company expected to realize \$7M-\$9M of annualized synergies.<sup>6</sup> The Company has already realized approximately \$7M of annualized expense synergies through headcount reductions and reduction in public company costs. Management continues to focus on further expense reduction opportunities.

**Strong Balance Sheet:** As at the end of Q3 2023, the Company maintained \$13.0M in cash and cash equivalents with less than \$3M of debt. This cash balance does not include the \$7.3M collected subsequent to the quarter from the settlement of a long outstanding dispute noted previously. This financial position is expected to give MediPharm longevity to execute on its short-term sales plans and provides the balance sheet strength to support the Company's long-term growth strategy including selective mergers and

---

<sup>5</sup> Adjusted EBITDA is a non-IFRS measure. See "Reconciliation of non-IFRS Measures" for reconciliation to IFRS measures.

<sup>6</sup> This forward-looking statement is based on the following material factors and assumptions: (a) assumes that both costs and revenue opportunities identified and the forecasts derived collaboratively by MediPharm and VIVO management teams will be achieved, (b) revenue opportunity assumes that existing products may be sold into the existing sales channels of both VIVO and MediPharm, (c) costs savings estimate depends on the eliminating duplicated public company expenses and redundant corporate infrastructure, and (d) assumes the estimated revenue and cost synergies may be achieved in the near term. This target, and the related assumptions, involve known and unknown risks and uncertainties that may cause actual results to differ materially. While MediPharm and VIVO believe there is a reasonable basis for this target, such target may not be met. Actual results may vary and differ materially from the targets. See "Cautionary Note Regarding Forward-Looking Statements" and "Risk Factors".

acquisitions. This balance sheet strength puts MediPharm in a strong position relative to many of our peer group who are largely burdened with excessive debt, unpaid excise duties and significantly stretched accounts payables.

**Corporate Governance:** David Pidduck joined MediPharm Labs as Chief Executive Officer and Director, in April 2022. Mr. Pidduck brings more than 20 years of proven senior leadership experience, including serving as President and CEO of a Canadian pharmaceutical company, where he was also a member of the board of directors. Over his career, Mr. Pidduck has been involved in the successful ground-up commercialization of several products in both Canadian and international markets and brings a track record of both organic execution as well as M&A and integration expertise to the Company. Aside from Mr. Pidduck, the Company's Board of Directors consists solely of experienced independent directors. Effective April 1, 2023, in connection with the Arrangement, Dr. Michael Bumby was appointed to the Board of Directors.

**Domestic Presence:** We added to the innovative, pharma-quality family of branded materials with the retail introduction of new products such as new naturally derived oil and inhalable CBG to build on the Company's wellness portfolio. MediPharm was awarded CBD Brand of the year, for the second time, and CBN product of the year from KIND Magazine. An award voted on by frontline cannabis retailers, signifying our leadership in the cannabis wellness space. MediPharm currently has the second highest market share in Canadian cannabis oil.<sup>7</sup> With the removal of the Shelter Brand royalty payment on the dry flower products branded Wildlife, MediPharm continues to improve gross profit in this adult use sub-category. Subsequent to the quarter in November 2023, the company expanded its oil portfolio to include three new oil SKUs including a highly requested THC and CBD balanced oil.

**Unique Suite of Licences and Authorizations:** The Company has built on an industry-leading and expanding portfolio of licences by recently receiving a DEL (Drug Establishment Licence) from Health Canada, which is required to produce pharmaceutical prescription drugs with marketing authorization. This allows for the participation in clinical trials and partnerships with other pharmaceutical companies that could result in potentially patentable intellectual property. The Company leveraged its collection of licences to enter into a research master agreement with McMaster University for participation in various cannabis based clinical trials and to enter into a research support agreement with the Keck School of Medicine of University of Southern California to conduct a Phase 2 trial on the efficacy of THC and CBD to treat hospice-eligible patients diagnosed with dementia and experiencing agitation. During the 2022 fiscal year, the Company has leveraged the DEL to register CBD API with the FDA for commercial opportunities in pharmaceutical development, novel drugs, and generic drugs. This is a first and makes the Company the only Canadian company to register a CBD API DMF with the US FDA.<sup>8</sup>

The Company's Napanee Facility holds a Part 1 and Part 2 EU GMP licence issued by the German Federal Institute for Drugs and Medical Devices. This allows the flower production and packaging of EU GMP products destined for Australia, Germany and the United Kingdom. With the possibility of additional European Union countries in the future as medical cannabis regulations evolve.

**Clinical Research with Cannabinoids:** MediPharm remains focused on supporting clinical research and supporting the development of future cannabis derived pharmaceutical drugs. Consistent with this commitment, the Company will supply the sponsor and principal investigators with cannabis-derived study drugs, placebos, and other services and assistance as may be required during the course of the studies. This

---

<sup>7</sup> As reported by HiFyre Retail Analytics on March 21, 2023, available online.

<sup>8</sup> According to the FDA Drug Master File List last updated in Q4 2022, available online.

**MediPharm Labs Corp.**  
**MANAGEMENT'S DISCUSSION AND ANALYSIS**  
**For the three and nine months ended September 30, 2023**  
**(All amounts disclosed are expressed in Canadian dollars (C\$'000s) unless otherwise stated.)**

---

CTM is provided for a fee and any contributions made in-kind are in relation to intangible future benefit to the Company.

The following update provides current milestone achievements of notable projects.

Researcher	Indication	Phase	Recent Milestone
USC (University of Southern California) Keck School of Medicine	Treatment of Alzheimer's Agitation Disorder	Phase 2	FDA approval of Investigational New Drug (IND) Clinical trial material (CTM) delivered and enrollment commencing in Q3 2023 Second CTM delivery approval from US DEA has been received.
McMaster University	Treatment of post-surgical pain	Phase 2	CTM delivered and enrollment commenced in Q1 2023 Patient dosing commenced in Q2 2023.
University Health Network – Toronto	Improving Pain Disability With The Use Of Oral Cannabinoids	Pilot	CTM Delivered and enrollment clinic in Q1 2023
McMaster University	Insomnia in depressive disorder	Phase 2	CTM Shipment in Q1 2023 Patient dosing commenced in Q2 2023.
Centre for Medical Cannabis Research	PK of single dose THC/CBD in healthy adult controls and kidney disease	Phase 1	1 <sup>st</sup> patient dosed January 2023
University of Manitoba	Chronic Headaches in Adolescents	Phase 2	Health Canada approval Dec 2022. CTM shipment in Q1 2023

In addition to these institutionally led studies, the Company is also providing API and clinical trial material to various pharmaceutical companies for commercial projects involving cannabis-derived drugs. The timelines for both institutional and industry research are long by nature with positive outcomes uncertain.

**SUMMARY OF QUARTERLY RESULTS**

The following tables set out the Company's selected quarterly consolidated financial information:

	Three months ended			
	September 30, 2023 \$'000s	June 30, 2023 \$'000s	March 31, 2023 \$'000s	December 31, 2022 \$'000s
Revenue	8,505	9,583	5,843	5,616
Gross profit before realized fair value adjustment on sale of cannabis inventory acquired in a business combination	2,919	1,443	387	211
Gross profit before change in fair value of biological assets	864	1,443	387	211
Gross profit	2,417	855	387	211
General administrative expenses	(4,314)	(5,796)	(1,518)	(3,371)
Marketing and selling expenses	(1,675)	(1,667)	(1,369)	(1,607)
R&D expenses	(61)	(53)	(36)	(144)
Share based compensation expense	(386)	(588)	(747)	(1,390)
Other operating income/(expense), net	(336)	(380)	(50)	(89)
Operating loss	(4,355)	(7,629)	(3,333)	(6,390)
Net loss	(4,327)	(2,703)	(3,088)	(5,609)
Loss per share – basic and diluted	(0.01)	(0.01)	(0.01)	(0.02)
Adjusted EBITDA <sup>(1)</sup>	(2,346)	(3,191)	(3,090)	(3,634)

	Three months ended			
	September 30, 2022 \$'000s	June 30, 2022 \$'000s	March 31, 2022 \$'000s	December 31, 2021 \$'000s
Revenue	7,262	4,362	4,877	5,743
Gross profit	(1,190)	(532)	(403)	(4,973)
General administrative expenses	(3,543)	(4,746)	(4,886)	(10,429)
Marketing and selling expenses	(1,651)	(1,553)	(1,493)	(1,414)
R&D expenses	(250)	(308)	(300)	(582)
Share based compensation expense	(161)	(580)	(741)	(611)
Other operating income/(expense), net	(1,251)	(1,350)	319	(4,156)

	Three months ended			
	September 30, 2022 \$'000s	June 30, 2022 \$'000s	March 31, 2022 \$'000s	December 31, 2021 \$'000s
Operating loss	(8,046)	(9,069)	(7,504)	(22,165)
Net loss	(7,930)	(8,987)	(7,457)	(21,766)
Loss per share – basic and diluted	(0.03)	(0.03)	(0.03)	(0.08)
Adjusted EBITDA <sup>(1)</sup>	(4,974)	(6,345)	(5,684)	(6,573)

(1) Adjusted EBITDA is a non-IFRS measures. See "Reconciliation of non-IFRS Measures" for reconciliation to IFRS measures.

## DISCUSSION OF OPERATIONS

### Revenue

As of the date of this MD&A, our core business generates revenue through four primary streams, being Canadian Adult Use and Wellness, Canadian Medical Cannabis, International Medical Cannabis and Pharmaceutical and B2B, as described previously.

### Cost of goods sold

Cost of sales reflects the cost to extract and process the cannabis concentrates as well as the management of product throughput and inventory levels. Cost of sales includes the purchase of material and services such as the purchase of dried cannabis, inbound freight expenses, a portion of insurance expenses, employee wages and benefit costs, and other operating expenses such as repairs and maintenance, plant overhead, fair value adjustments of as well as depreciation and any write-downs of inventory and manufacturing equipment.

### Biological Assets

Biological assets consist of cannabis plants at various stages of growth (pre-harvest) being cultivated by the Company. The value of these plants is recorded on the balance sheet as biological assets at their anticipated fair value less costs to harvest, package and sell. At harvest, the cumulative biological asset value of these plants is transferred from biological assets to inventory. This biological asset value is thereby 'embedded' in the value of the Company's inventory. Further post-harvest processing expenses are capitalized to inventory. When sold, the value of the capitalized post-harvest processing expenses within the sold inventory are expensed to 'cost of inventory sold', and the biological asset value embedded in the inventory is booked to 'realized gain on biological transformation' on the statement of losses.

All pre-harvest expenses attributable to the cultivation of plants, including both direct and indirect expenses, are expensed as production costs in the period in which they are incurred. They are not capitalized to biological assets and therefore are never included in inventory.

### Gross Profit

Gross profit is calculated by deducting the cost of sales and fair value adjustments of biological assets from revenue. The Company continues to refine its production processes and methodologies, and sell through

historically acquired higher priced raw materials, and expects to increase production efficiency and gross profit.

#### **General administrative expenses**

General administrative expenses include personnel expenses, consulting and professional fees, depreciation and amortization, travel and entertainment expenses, bad debt expenses, insurance expenses, occupancy cost, filing fees and other expenses related to the infrastructure required to support our business.

#### **Marketing and selling expenses**

Marketing and selling expenses include investor relations expenses, advertising and promotion expenses, personnel expenses, travel and entertainment expenses, freight to customer and other expenses incurred to win new business and retain existing clients.

#### **R&D expenses**

R&D expenses currently include expenses related to working on new product lines, a portion of depreciation expense and wages and benefits cost.

#### **Share-based compensation expense**

Share-based compensation expense represents fair value of stock options and RSUs granted to employees and recognised over the vesting period.

#### **Other operating expenses**

Other operating expenses include foreign exchange loss, impairment of property, plant and equipment and intangibles, wage and rent subsidies and bank and financial institution service fees, which are costs that do not depend on sales or production quantities.

#### **Finance income**

Finance income comprises interest income earned on cash balance and short-term investments.

#### **Finance expense**

Finance expense comprises finance fees and interest expenses that were incurred on the loans and convertible notes.

#### **Unrealized gain in revaluation of derivative liabilities**

Unrealized gain in revaluation of derivative liabilities pertains to the revaluation gain on the warrant derivative liability and the conversion option derivative liability.

#### **Gain on bargain purchase**

Gain on bargain purchase represents gain on business combination.

#### **Taxation expense**

Taxation expense reflects the Company's income tax expense and deferred tax expense or recovery.

### Other Comprehensive Income and Loss

Other comprehensive income and loss includes exchange gains and losses on translation of foreign operations.

### Discussion and Analysis of the Results for the Three-Month Period Ended September 30, 2023

Results of operations for the three months ended September 30, 2023, as compared to the three months ended September 30, 2022.

	Three months ended			Management Commentary
	September 30		\$	
	2023	2022		
	\$'000s	\$'000s	\$	
Revenue	8,505	7,262	1,243	Revenue increases \$1.2M or 17% versus prior year largely driven by the acquisition of VIVO and partially offset by the divestiture of the Australian subsidiary. See operational highlights section for more details.
Cost of sales	(5,586)	(8,452)	2,866	The decrease was driven by the ongoing realization of efficiencies and synergies resulting from the integration of the VIVO business.
Gross profit before realized fair value adjustment on sale of cannabis inventory acquired in a business combination	2,919	(1,190)	4,109	Gross profit continues to improve driven by product mix, production efficiencies, selective price increases and cost reductions. See operational highlights section for more details.
Incremental cost of cannabis inventory acquired in a business combination <sup>(2)</sup>	(2,055)	-	(2,055)	The increase is due to gains realized on inventory acquired with the acquisition of the VIVO business.
Gross profit before change in fair value of biological assets	864	(1,190)	2,054	Gross profit continues to improve driven by product mix, production efficiencies, selective price increases and cost reductions, offset by impact of realized fair value adjustment on sale of cannabis inventory acquired in a business combination. See operational highlights section for more details.
Gross profit	2,417	(1,190)	3,607	Gross profit continues to improve driven by product mix, production efficiencies, selective price increases and cost reductions, offset by impact of fair value changes in biological assets. See operational highlights section for more details.
General administrative expenses	(4,314)	(3,543)	(771)	Expenses increased primarily due to the integration of VIVO. This is offset by ongoing realization of efficiencies and synergies to reduce costs. G&A costs are down \$3.2M or 42% when compared with the combined companies previous period's costs.

MediPharm Labs Corp.  
**MANAGEMENT'S DISCUSSION AND ANALYSIS**  
**For the three and nine months ended September 30, 2023**  
**(All amounts disclosed are expressed in Canadian dollars (C\$'000s) unless otherwise stated.)**

	Three months ended			\$	Management Commentary
	September 30				
	2023	2022			
	\$'000s	\$'000s			
Marketing and selling expenses	(1,675)	(1,651)	(24)	Expenses are in line with the prior period due to ongoing cost reduction measures offsetting increases from the integration of VIVO.	
R&D expenses	(61)	(250)	189	Expenses reduced mainly due to the MPLA Divestment and restructuring during 2022.	
Share-based compensation expenses	(386)	(161)	(225)	Expense increased due issuance of Options and RSUs during the period.	
Other operating (expense)/income, net	(336)	(1,251)	915	Expenses decreased mainly because of the impact of foreign exchange differences largely due to foreign currency denominated intercompany loans.	
<b>Operating loss</b>	(4,355)	(8,046)	3,691	See comments above.	
<b>Adjusted EBITDA <sup>(1)</sup></b>	(2,346)	(4,974)	2,628	Adjusted EBITDA is a non-IFRS measure. See "Reconciliation of non-IFRS Measures" for reconciliation to IFRS measures.	
Finance income	174	132	42	Increased as a result of higher interest rate on deposits.	
Finance expense	(149)	(16)	(133)	Increased as a result of financing costs on the convertible debenture and the Company's insurance premium financing arrangement.	
<b>Loss before taxation</b>	(4,330)	(7,930)	3,600	See comments above.	
<b>Net loss for the period</b>	(4,327)	(7,930)	3,603	See comments above.	

- (1) Incremental cost of cannabis inventory acquired in a business combination represents the fair value realized on sale of cannabis inventory acquired in a business combination.
- (2) Adjusted EBITDA is a non-IFRS measure. See "Reconciliation of non-IFRS Measures" for reconciliation to IFRS measures.

## RECONCILIATION OF NON-IFRS MEASURES

The following section provides reconciliations of the supplemental non-IFRS financial measures used in this MD&A, compared to the most directly comparable financial measures calculated and presented in accordance with IFRS. The Company has provided the non-IFRS financial measures, which are not calculated or presented in accordance with IFRS, as supplemental information.

These supplemental non-IFRS financial measures are presented because management has evaluated the financial results of the Company, both including and excluding adjusted items, and believes that the supplemental non-IFRS financial measures presented provide additional perspective and insight when analyzing operating performance. These supplemental non-IFRS measures should not be considered superior to, a substitute for, or as an alternative to and should be read in conjunction with the IFRS financial measures presented.

## Adjusted EBITDA

Adjusted EBITDA is a metric used by management which is net operating loss adjusted for interest, provisions for income taxes, other non-cash items including depreciation and amortization, share-based compensation, derivative liabilities, and extraordinary and non-recurring items.

The following table reconciles the Company's net operating income (loss) (as reported) and Adjusted EBITDA for the periods presented.

	Three months ended		Nine months ended	
	September 30, 2023 \$'000s	September 30, 2022 \$'000s	September 30, 2023 \$'000s	September 30, 2022 \$'000s
<b>Net operating loss</b>	(4,355)	(8,046)	(15,317)	(24,619)
Adjusted for:				
Share-based compensation expense	386	161	1,721	1,482
Depreciation and amortization	617	754	1,799	2,332
Restructuring related severance expenses	273	-	1,968	1,233
Government grants	-	-	-	(21)
Transaction fees	46	185	883	351
Recovery of impaired receivables <sup>(1)</sup>	-	-	(2,010)	-
Impairment loss on remeasurement of disposal group	-	1,476	-	1,476
Impairment loss on remeasurement of assets held for sale	17	68	17	68
Incremental cost of cannabis inventory acquired in a business combination <sup>(2)</sup>	2,055	-	2,055	-
Fair value adjustments in gross profit	(1,553)	-	(965)	-
Write down of inventories <sup>(3)</sup>	168	428	1,204	766
<b>Adjusted EBITDA</b>	<b>(2,346)</b>	<b>(4,974)</b>	<b>(8,645)</b>	<b>(16,932)</b>

- (1) This relates to the reversal of a former impairment of a long outstanding receivable.
- (2) Incremental cost of cannabis inventory acquired in a business combination represents the fair value realized on sale of cannabis inventory acquired in a business combination.
- (3) This adjustment is for unusual inventory write-downs only and not the total value of inventory written down.

## CAPITAL STRUCTURE

### *Common Shares*

The Company's authorized capital consists of an unlimited number of Common Shares. As at September 30, 2023, the Company had 399,573,661 Common Shares issued and outstanding, and as at the date of this MD&A, the Company has 401,280,748 Common Shares issued and outstanding.

### *Warrants*

On June 8, 2020, the Company closed a private placement with an institutional investor for gross proceeds of \$37.8 million through the issuance of (the "**2020 Private Placement**"): (i) a \$20.5 million senior unsecured convertible note (the "**First Note**"); (ii) a warrant to purchase up to 3,601,427 Common Shares (the "**First Warrant**"), and (ii) a subscription receipt entitling the holder to receive, upon satisfaction of certain escrow release conditions, a further \$20.5 million senior unsecured convertible note (the "**Second Note**" and, together with the First Note, collectively, the "**Notes**") and a further warrant (the "**Second Warrant**" and, together with the First Warrant, collectively, the "**2020 Warrants**") to purchase up to an additional 3,601,427 Common Shares. On August 6, 2020, the escrow release conditions were satisfied, and the subscription receipt was exchanged for the Second Note and Second Warrant. As of September 30, 2023 and the date of this MD&A, the Company had nil principal amount outstanding under the Notes. As at September 30, 2023, the Company had issued and outstanding 2020 Warrants exercisable to acquire up to an aggregate of 7,202,854 Common Shares at an exercise price of \$2.28 per Common Share until October 9, 2023. As at the date of this MD&A, the 2020 Warrants expired, with nil 2020 Warrants remaining issued and outstanding.

Following Closing of the Arrangement, the Warrants listed on the TSX under the trading symbol "VIVO.WT" continued trading on the TSX under the symbol "LABS.WT.B". Each Warrant is exercisable into 0.2910 of a Common Share (each whole share, a "**Warrant Share**") at an exercise price equal to \$0.26 per 0.2910 of a Warrant Share. The Warrants expire on February 26, 2024. As of September 30, 2023 and the date of this MD&A, there were 19,166,667 Warrants issued and outstanding exercisable to acquire up to 5,577,500 Common Shares.

### *Stock Options and RSUs*

As at September 30, 2023, options to purchase up to 28,245,685 Common Shares were issued and outstanding. During the nine months ended September 30, 2023, 2,559,847 options to purchase Common Shares were granted, nil options to purchase Common Shares were exercised, and options to purchase 956,300 Common Shares were forfeited, cancelled and/or expired.

As at September 30, 2023, RSUs representing the right to acquire up to 10,555,530 Common Shares were issued and outstanding. During the nine months ended September 30, 2023, 1,298,399 RSUs were granted, 9,477,791 RSUs were settled through the issuance of Common Shares and 67,712 RSUs were forfeited, cancelled and/or expired.

Subsequent to September 30, 2023, nil options were issued, 300,268 options were forfeited/cancelled and nil options were exercised resulting in 27,945,417 options remaining outstanding as of the date of this MD&A.

Subsequent to September 30, 2023, nil RSUs were issued, 10,830RSUs were forfeited/cancelled and 1,707,087 RSUs were settled resulting in 8,837,613 RSUs remaining outstanding as of the date of this MD&A.

### *Debentures*

Following closing of the Arrangement, the Company assumed the covenants and conditions associated with the debentures (the “**Debentures**”) convertible into common shares in the capital of VIVO (the “**VIVO Shares**”), pursuant to a fourth supplemental debenture indenture dated as of April 1, 2023, relating to the Debentures. The Debentures are due September 15, 2024 and are convertible into, in lieu of the number of VIVO Shares to which such holder was entitled, such number of Common under the Arrangement that such holder would have been entitled to receive if, immediately prior to closing of the Arrangement, such holder had been the registered holder of the number of VIVO Shares underlying the Debentures. As of September 30, 2023, and the date of this MD&A, \$2,047 principal amount of debentures are issued and outstanding.

## **LIQUIDITY AND CAPITAL RESOURCES**

### **Liquidity**

Management's objectives when managing the Company's liquidity and capital structure are to generate sufficient cash to fund the Company's operating and growth strategy. The Company constantly monitors and manages its capital resources to assess the liquidity necessary to fund operations and capacity expansion.

During the nine months ended September 30, 2023, the Company used cash in operating activities of \$13,813 (September 30, 2022 - \$15,901). As of September 30, 2023, the Company had a working capital balance of \$28,947 (December 31, 2022 - \$37,889) and an accumulated deficit of \$173,767 (December 31, 2022 - \$163,649). As of September 30, 2023, the Company had cash and cash equivalents of \$12,950 (December 31, 2022 - \$24,145).

The Company completed the Arrangement on April 1, 2023. Without achieving significant synergies for the combined entity after the Arrangement or obtaining additional financing, the Arrangement will result in the use of the Company's existing cash and cash equivalents to fund the operations of VIVO. The Company's ability to continue as a going concern following completion of the Arrangement is dependent upon its ability to generate sufficient revenues and positive cash flow from its operating activities and/or obtaining sufficient funding to meet its plans and obligations.

Using forecasts derived collaboratively by both management teams, along with revenue and cost synergy estimates, the pro-forma combined company aims to find positive EBITDA synergies to the magnitude of between \$7 million to \$9 million on an annualized basis and has a goal to reach positive adjusted EBITDA and cash flow in 2024.<sup>9</sup>

Management of the Company believes the Company's current resources are sufficient to settle its current liabilities, when considering inventory, trade receivables and cash and cash equivalents.

---

<sup>9</sup> This forward-looking statement is based on the following material factors and assumptions: (a) assumes that both costs and revenue opportunities identified and the forecasts derived collaboratively by MediPharm and VIVO management teams will be achieved, (b) revenue opportunity assumes that existing products may be sold into the existing sales channels of both VIVO and MediPharm, (c) costs savings estimate depends on the eliminating duplicated public company expenses and redundant corporate

**MediPharm Labs Corp.**  
**MANAGEMENT'S DISCUSSION AND ANALYSIS**  
**For the three and nine months ended September 30, 2023**  
**(All amounts disclosed are expressed in Canadian dollars (C\$'000s) unless otherwise stated.)**

The following table presents the net cash flows for each of the periods presented:

	Nine months ended			Management Commentary
	September 30			
	2023 \$'000s	2022 \$'000s	Change	
Cash and cash equivalents, beginning of period	24,145	34,110	(9,965)	
Net cash used in operating activities	(13,813)	(15,901)	2,088	Negative cashflow from operating activities mainly due to operating loss. The decrease in operating loss is mainly due to cost reductions and production efficiencies.
Net cash from investing activities	2,564	(547)	3,111	The increase is due to cash acquired from the business combination and sale of certain property acquired from the business combination.
Net cash from financing activities	(127)	1,195	(1,322)	The net cash outflow during the period comprises receipt of new insurance premium finance and repayment of debenture and existing premium financing during period compared with just receipt of insurance premium financing in the comparative period.
Effect of exchange rate change on cash and cash equivalents	181	597	(416)	
Cash and cash equivalents, end of period	12,950	19,454	(6,504)	Refer to comments above. This cash balance does not include the \$7.3M received from the Tilray settlement subsequent to quarter end.

### Contractual Obligations

The Company's contractual obligations as at September 30, 2023, increased by \$5,289 as compared to December 31, 2022, mainly as a result of increases in trade payables and the recognition of convertible debt on the acquisition of VIVO.

Contractual Obligations	Payments due by Period \$'000s				
	Total	< 1 year	1-3 years	4-5 years	> 5 years
Loans and borrowings	648	648	-	-	-

infrastructure, and (d) assumes the estimated revenue and cost synergies may be achieved in the near term. This target, and the related assumptions, involve known and unknown risks and uncertainties that may cause actual results to differ materially. While MediPharm and VIVO believe there is a reasonable basis for this target, such target may not be met. Actual results may vary and differ materially from the targets. See "Cautionary Note Regarding Forward-Looking Statements" and "Risk Factors".

Contractual Obligations	Payments due by Period \$'000s				
	Total	< 1 year	1-3 years	4-5 years	> 5 years
Convertible debt	2,047	2,047	-	-	-
Lease Liabilities	263	182	81	-	-
Employee benefit obligations	2,069	2,069	-	-	-
Trade and other payables	8,015	8,015	-	-	-
<b>Total contractual obligations</b>	<b>13,042</b>	<b>12,961</b>	<b>81</b>	<b>-</b>	<b>-</b>

### Capital Resources

As of September 30, 2023, the Company does not have any commitments for capital expenditures. The Company is continually evaluating various debt and/or equity financing opportunities to lower its cost of capital and optimize its capital structure.

The Company is subject to risks including, but not limited to, its inability to raise additional funds through debt and/or equity financing to support its continued operations and to meet its liabilities and commitments as they come due. See "Risk Factors".

### OFF BALANCE SHEET ARRANGEMENTS

The Company has no off-balance sheet arrangements.

### RELATED PARTY TRANSACTIONS

See Note 20 of the Financial Statements. Other than compensation of key management personnel, the Company had no transactions with related parties.

### RISK FACTORS

There are a number of risk factors that could impact the Company's ability to successfully execute its key strategies and may materially affect future events, performance, or results, including without limitation the following risk factors discussed in greater detail under the heading "Risk Factors" in the Annual Information Form available on [www.sedar.com](http://www.sedar.com), which risk factors are incorporated by reference into this document and should be reviewed in detail by all readers:

- negative operating cash flow and ability to continue as a going concern;
- limited operating history;
- regulatory compliance risks;
- change of cannabis laws, regulations and guidelines;
- reliance on licences and authorizations;
- lack of long-term client commitments;
- COVID-19 pandemic;

- disruption of supply chain;
- risks relating to R&D milestones and the Company's equipment;
- client and receivables risks;
- realization of growth targets including expansion of facilities and operations;
- management of growth;
- history of net losses;
- difficulty to forecast;
- competition;
- competition from illicit market;
- inability to sustain pricing and inventory models;
- conflicts of interest;
- legal proceedings;
- product liability;
- unknown health impact with use of cannabis products;
- product recall;
- insurance and uninsured risks;
- environmental regulation and risks;
- climate change risks;
- unfavourable publicity or consumer perception;
- catastrophic events;
- reliance on production facilities;
- information technology system and cyber attack risks;
- dependence on supply of cannabis and other key inputs;
- maintenance of effective quality control systems;
- retention and acquisition of skilled personnel;
- publication of negative results of clinical trials;
- failure to comply with laws in all jurisdictions;
- United States of America entry restrictions;
- perceived reputational risk for third parties;
- risks related to intellectual property;
- anti-money laundering laws and regulation risks;
- anti-bribery law violations;
- marketing constraints;
- research and development;
- shelf life of inventory;
- scheduled maintenance, unplanned repairs, equipment outages and logistical disruptions;
- risks as a result of international expansions;
- operations in foreign jurisdictions;

- reliance upon international advisors and consultants;
- foreign currency risk;
- Russian invasion of Ukraine;
- acquisition and integration risk;
- access to capital;
- estimates or judgments relating to critical accounting policies;
- tax risks;
- negative operating cash flow;
- inflation risk;
- market for the Common Shares;
- significant fluctuations in the market price of the Common Shares;
- investment in the cannabis sector;
- no history of payment of cash dividends;
- reporting issuer status;
- significant sales of Common Shares;
- analyst coverage;
- tax issues related to the Common Shares;
- market for future offerings of securities;
- future sales affecting market price; and
- management discretion concerning use of proceeds.

In addition, the Company highlights the following risk factors:

*Financial Projections May Differ Materially*

The board of directors of VIVO and the Board considered, among other things, certain projections, prepared by their respective management teams, with respect to each of the Company (the “**MediPharm Projections**”) and VIVO (the “**VIVO Projections**”, together with the MediPharm Projections, the “**Projections**”) in connection with the Arrangement. All Projections are based on assumptions and information available at the time the Projections were prepared. The Company does not know whether the assumptions made will be realized. Such information can be adversely affected by known or unknown risks and uncertainties, many of which are beyond the Company’s control. Further, financial forecasts of this type are based on estimates and assumptions that are inherently subject to risks and other factors such as company performance, industry performance, legal and regulatory developments, general business, economic, regulatory, market and financial conditions, as well as changes to the business, financial condition or results of operations of VIVO and the Company, including the factors described in this “Risk Factors” section which factors and changes may impact such forecasts or the underlying assumptions. As a result of these contingencies, there can be no assurance that the Projections will be realized or that actual results will not be significantly higher or lower than projected. In view of these uncertainties, the Projections should not be regarded as an indication that the Company and the Board, or any of their advisors or any other recipient of this information considered, or now considers, it to be an assurance of the achievement of future results. The Projections were prepared by VIVO and the Company’s management teams for internal use and to, among other things, assist VIVO and the Company in evaluating the Arrangement. The Projections were not prepared with a view toward public disclosure or toward compliance with IFRS,

published guidelines of applicable securities regulatory authorities or the guidelines established by the Chartered Professional Accountants for preparation and presentation of prospective financial information. Neither MNP LLP, VIVO's independent registered public accounting firm, MNP LLP, the Company's independent registered public accounting firm, nor any other independent accountants, have compiled, examined, or performed any procedures with respect to the Projections, nor have they expressed any opinion or any other form of assurance on such information or its achievability, and assume no responsibility for, and disclaim any association with, the Projections.

#### **CRITICAL ACCOUNTING ESTIMATES**

See Note 2.4 of the Financial Statements.

#### **CHANGES IN ACCOUNTING POLICIES**

There have been no material changes to our critical accounting estimates and policies during the three and nine months ended September 30, 2023.

#### **DISCLOSURE CONTROLS AND INTERNAL CONTROLS**

Management maintains appropriate information systems, procedures, and controls to provide reasonable assurance that information that is publicly disclosed is complete, reliable, and timely. The Chief Executive Officer (the "CEO") and Chief Financial Officer (the "CFO") of the Company, along with the assistance of senior management under their supervision, have designed disclosure controls and procedures to provide reasonable assurance that material information relating to the Company is made known to the CEO and CFO, and have designed internal controls over financial reporting to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with IFRS.

No changes were made in our design of internal controls over financial reporting during the three and nine months ended September 30, 2023, that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

It should be noted that a control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance of control issues, including whether instances of fraud, if any, have been detected. These inherent limitations include, among other items: (i) that management's assumptions and judgments could ultimately prove to be incorrect under varying conditions and circumstances; (ii) the impact of any undetected errors; and (iii) that controls may be circumvented by the unauthorized acts of individuals, by collusion of two or more people, or by management override.

#### **DISCLOSURE FOR ISSUERS WITH U.S. MARIJUANA-RELATED ACTIVITIES**

On February 8, 2018, the Canadian Securities Administrators published the Staff Notice which provides specific disclosure expectations for issuers that currently have, or are in the process of developing, cannabis-related activities in the U.S. as permitted within a particular state's regulatory framework. All issuers with U.S. cannabis-related activities are expected to clearly and prominently disclose certain prescribed information in required disclosure documents. Different disclosures are required to the extent a reporting issuer is deemed to be directly or indirectly engaged in the U.S. cannabis industry, or deemed to have

MediPharm Labs Corp.

MANAGEMENT'S DISCUSSION AND ANALYSIS

For the three and nine months ended September 30, 2023

(All amounts disclosed are expressed in Canadian dollars (C\$'000s) unless otherwise stated.)

---

“ancillary industry involvement”, all as further described in the Staff Notice.

As of the date of this MD&A, the Company is not involved in activities that, according to the Staff Notice, would categorize the Company as an issuer with U.S. marijuana-related activities, specifically any cultivation, possession or distribution of marijuana that is illegal under U.S. federal law. The Company's current plans to supply approved CBD APIs to pharmaceutical companies conducting late-stage research, pursuant to its FDA DMF filing (the “**U.S. Activities**”) will be completed in accordance with the appropriate U.S. federal laws under which the Company's activities are considered federally legal.

In accordance with the Staff Notice, the Company will evaluate, monitor and reassess this disclosure, and any related risks, on an ongoing basis and intends to supplement and amend the same to investors in public filings, including in the event of government policy changes or the introduction of new or amended guidance, laws or regulations regarding cannabis regulation. As of the date of this MD&A, the Company has no direct or indirect cannabis-related activity outside of the U.S. Activities that would require additional disclosure pursuant to the Staff Notice.